Avantor (NYSE:AVTR) PT Lowered to $25.00 at Barclays

Avantor (NYSE:AVTR) had its price objective decreased by equities researchers at Barclays from $28.00 to $25.00 in a note issued to investors on Friday, Benzinga reports. The firm presently has an “overweight” rating on the stock. Barclays‘s price objective would indicate a potential upside of 17.26% from the stock’s current price.

Other equities research analysts also recently issued research reports about the stock. Deutsche Bank Aktiengesellschaft raised their price target on shares of Avantor from $23.00 to $25.00 and gave the company a “hold” rating in a research report on Thursday, April 18th. Robert W. Baird lowered their price target on Avantor from $27.00 to $26.00 and set an “outperform” rating on the stock in a report on Monday, April 29th. Finally, Evercore ISI lifted their price objective on Avantor from $26.00 to $28.00 and gave the stock an “outperform” rating in a report on Thursday, April 4th. Four analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company. According to data from MarketBeat.com, Avantor currently has an average rating of “Moderate Buy” and a consensus target price of $26.36.

Avantor Trading Down 0.5 %

Shares of NYSE:AVTR traded down $0.10 on Friday, hitting $21.32. The company had a trading volume of 2,349,903 shares, compared to its average volume of 5,769,126. Avantor has a 1 year low of $16.63 and a 1 year high of $26.16. The firm’s 50-day simple moving average is $23.85 and its two-hundred day simple moving average is $23.81. The company has a quick ratio of 1.05, a current ratio of 1.61 and a debt-to-equity ratio of 0.94. The firm has a market capitalization of $14.48 billion, a price-to-earnings ratio of 54.67, a P/E/G ratio of 2.23 and a beta of 1.35.

Avantor (NYSE:AVTR) last announced its earnings results on Friday, April 26th. The company reported $0.22 EPS for the quarter, beating analysts’ consensus estimates of $0.20 by $0.02. Avantor had a net margin of 3.79% and a return on equity of 13.01%. The firm had revenue of $1.68 billion for the quarter, compared to analysts’ expectations of $1.68 billion. During the same quarter in the previous year, the business posted $0.29 EPS. The company’s quarterly revenue was down 5.6% on a year-over-year basis. Equities analysts anticipate that Avantor will post 1.01 earnings per share for the current fiscal year.

Institutional Trading of Avantor

Several hedge funds and other institutional investors have recently bought and sold shares of AVTR. Vanguard Group Inc. lifted its stake in shares of Avantor by 0.3% during the 3rd quarter. Vanguard Group Inc. now owns 65,457,140 shares of the company’s stock worth $1,379,837,000 after purchasing an additional 211,189 shares during the last quarter. Boston Partners lifted its position in Avantor by 2.2% during the first quarter. Boston Partners now owns 28,561,802 shares of the company’s stock valued at $729,298,000 after acquiring an additional 624,369 shares during the last quarter. Artemis Investment Management LLP boosted its stake in Avantor by 14.9% in the first quarter. Artemis Investment Management LLP now owns 9,120,083 shares of the company’s stock valued at $233,109,000 after acquiring an additional 1,180,937 shares in the last quarter. Bessemer Group Inc. grew its holdings in Avantor by 4.4% in the first quarter. Bessemer Group Inc. now owns 7,099,848 shares of the company’s stock worth $181,544,000 after purchasing an additional 297,534 shares during the last quarter. Finally, Norges Bank acquired a new stake in shares of Avantor in the 4th quarter worth $156,455,000. Hedge funds and other institutional investors own 95.08% of the company’s stock.

Avantor Company Profile

Avantor, Inc engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, peristaltic pumps, and fluid handling tips.